Sierra Oncology’s $103 Million Public Offering of Convertible Preferred Stock and Warrants

Ambrogio Visconti

Fenwick & West represented Sierra Oncology, Inc. in the deal. Sierra Oncology, Inc. (NASDAQ: SRRA) issued its underwritten public offering of Series A convertible preferred stock,…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

…

This content is for Standard 1 Year members only.
Login Join Now